P1078: Early diagnostic criteria for Parkinson’s disease

2014 ◽  
Vol 125 ◽  
pp. S335-S336 ◽  
Author(s):  
A. Kacar ◽  
M. Jankovic
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Diagnostic Criteria ◽  
Early Diagnostic

Multiple system atrophy mimicked by multi-organ pathology

2019 ◽  
Vol 19 (4) ◽  
pp. 350-351 ◽  
Author(s):  
Sana Khan ◽  
Gnanamurthy Sivakumar ◽  
Stuart Currie ◽  
Jane Alty
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Multiple System Atrophy ◽  
Diagnostic Criteria ◽  
Autonomic Dysfunction ◽  
Atypical Features

Both multiple system atrophy and Parkinson’s disease may present with parkinsonism and autonomic dysfunction. We describe a patient who initially met the diagnostic criteria for multiple system atrophy and had atypical features for Parkinson’s disease including blackouts and pyramidal signs. Ultimately, he was found to have three separate diagnoses rather than a single unifying one.

Diagnostic criteria for depression in Parkinson's disease: A study of symptom patterns using latent class analysis

2011 ◽  
Vol 26 (12) ◽  
pp. 2239-2245 ◽  
Author(s):  
Sergio Starkstein ◽  
Milan Dragovic ◽  
Ricardo Jorge ◽  
Simone Brockman ◽  
Marcelo Merello ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Latent Class Analysis ◽  
Diagnostic Criteria ◽  
Latent Class ◽  
Class Analysis ◽  
Symptom Patterns

A Précis of Recent Advances in the Neuropsychology of Mild Cognitive Impairment(s) in Parkinson's Disease and a Proposal of Preliminary Research Criteria

2011 ◽  
Vol 17 (3) ◽  
pp. 393-406 ◽  
Author(s):  
Alexander I. Tröster
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Diagnostic Criteria ◽  
Executive Dysfunction ◽  
Cognitive Change ◽  
Cognitive Changes ◽  
Preliminary Research ◽  
Research Criteria

AbstractCognitive changes of Parkinson's disease (PD) manifest earlier and are more heterogeneous than previously appreciated. Approximately one-third of patients have at least mild cognitive changes at PD diagnosis, and subtle changes might be appreciable among those at risk for PD. Executive dysfunction is the most common cognitive change, but other phenotypes exist. Pathobiologic and potential prognostic differences among cognitive phenotypes remain poorly understood. Progress in the neuropsychology, epidemiology and pathobiology of mild cognitive impairment (MCI) in PD is hampered by lack of diagnostic criteria. This study proposes preliminary research criteria for two categories of PD non-dementia cognitive impairment. (JINS, 2011,17, 393–406)

scholarly journals Clinical Presentation of Parkinson’s Disease: Experience of using Movement Disorder Society Clinical Diagnostic Criteria for Parkinson’s Disease

2021 ◽  
pp. 183-188
Author(s):  
Muhammad Rezeul Huq ◽  
M. A. Hannan ◽  
Md. Ahsan Habib ◽  
Ahad Mahmud Khan
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Movement Disorder ◽  
Diagnostic Criteria ◽  
Clinical Presentation ◽  
Neurodegenerative Disorder ◽  
Motor Symptom ◽  
Clinical Diagnostic ◽  
Movement Disorder Society ◽  
Clinical Diagnostic Criteria

Aims: Parkinson’s disease (PD) is a common neurodegenerative disorder. As no definite diagnostic tests are available, diagnosis is done mostly clinically. UK Brain Bank criteria is commonly used globally for that purpose. In this study we used Movement Disorder Society (MDS) Clinical Diagnostic Criteria to diagnose PD and document the clinical presentations. Study design: Descriptive cross-sectional study. Methodology: This study was carried out in the department of neurology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, from May 2018 to April 2019. Total 42 patients (4 clinically established and 38 clinically probable PD) were enrolled as study population according to Movement Disorder Society (MDS) Clinical Diagnostic Criteria - 2015 for PD. Their patterns of clinical presentation were recorded. Results: Among the PD patients, 31 were male and 11 were female. Mean age of all patients was 59.43 ± 11.34 years. The most common presenting feature was tremulous movement (90.5%) followed by slowness of movement (40.5%). Only 9% patients had early onset PD. All patients had history of positive response to dopaminergic therapy with documented resting tremor in 95.2%, and end-of-dose wearing off in 75.6%. Constipation was the commonest (69%) non motor symptom followed by sleep dysfunction (64.3%) & depression (50%). On examination- 100% patients had bradykinesia, 97.6% rest tremor, 95.2% rigidity, 21.4% mild dementia and 4.8% moderate dementia. Also 26.2% patients were found to have postural hypotension. 4 patients had red flag features- urinary retention was found in three patients and one patient suffered from recurrent early fall. Conclusion: MDS Clinical Diagnostic Criteria   help in accurate diagnosis of PD and include more clinical features which will help in formulating management plan.

scholarly journals Serum mBDNF and ProBDNF Expression Levels as Diagnosis Clue for Early Stage Parkinson's Disease

2021 ◽  
Vol 12 ◽  
Author(s):  
Xu Yi ◽  
Yujia Yang ◽  
Zhengfan Zhao ◽  
Manyu Xu ◽  
Yuan Zhang ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Early Stage ◽  
High Sensitivity ◽  
Serum Levels ◽  
Diagnostic Value ◽  
Diagnostic Techniques ◽  
Mature Brain ◽  
Early Diagnostic

Parkinson's disease (PD) is one of the most common chronic, progressive, and neurodegenerative diseases characterized clinically by resting tremor, bradykinesia, rigidity, and postural instability. As this disease is usually detected in the later stages, the cure is often delayed, ultimately leading to disability due to the lack of early diagnostic techniques. Therefore, it is of great importance to identify reliable biomarkers with high sensitivity and specificity for the early diagnosis of PD. In this study, we aimed to investigate whether serum expressions of mature brain-derived neurotrophic factor (mBDNF) and proBDNF can serve as biomarkers for the diagnosis of PD at early stage. One hundred and fifty-six patients with limb tremor and/or bradykinesia meeting the inclusion criteria were assigned to either ex-PD group (PD cases) or ex-NPD group (non-PD cases) and then reassigned to either po-PD group (with PD) or po-NPD group (without PD) at 1-year follow-up based on the results of the rediagnoses as performed in accordance with MDS Parkinson's diagnostic criteria. To improve early diagnostic accuracy, grouping (PD group and non-PD group) at initial visit and follow-up was performed differently and independently. Serum mBDNF and proBDNF levels were measured by enzyme-linked immunosorbent assays. The results demonstrated that serum levels of mBDNF and mBDNF/proBDNF were significantly lower in the ex-PD group (19.73 ± 7.31 and 0.09 ± 0.05 ng/ml) as compared with the ex-NPD group (23.47 ± 8.21 and 0.15 ± 0.12 ng/ml) (p < 0.01 for both) and in the po-PD group (19.24 ± 7.20 and 0.09 ± 0.05 ng/ml) as compared with the po-NPD group (25.05 ± 7.67 and 0.16 ± 0.14 ng/ml) (p < 0.01 for both). However, a significantly higher serum level of proBDNF was noted in the ex-PD group (235.49 ± 60.75 ng/ml) as compared with the ex-NPD group (191.75 ± 66.12 ng/ml) (p < 0.01) and in the po-PD group (235.56 ± 60.80 ng/ml) as compared with the po-NPD group (188.42 ± 65.08 ng/ml) (p < 0.01). In conclusion, mBDNF/proBDNF can be used as biomarkers for early stage Parkinson's disease; in addition, mBDNF plus proBDNF has better diagnostic value than mBDNF alone in the diagnosis of PD.

Sign in / Sign up

Export Citation Format

Share Document